Triple-Threat attack on blood cancer shows promise
NCT ID NCT02427451
Summary
This study is testing a combination of three different drugs (obinutuzumab, ibrutinib, and venetoclax) to treat chronic lymphocytic leukemia (CLL). It aims to find the safest dose and see how well the combination works for patients whose cancer has returned, is resistant to treatment, or who have never been treated before. The goal is to control the disease by using multiple approaches to stop cancer cell growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.